INTRODUCTION
The differentiation of benign and malignant intraosseous lesions can open be accomplished by means of radiographs, computed tomography (CT) and magnetic resonance imaging (MRI).
Radiographs including CT and X-ray provide important information about the appearance, intraosseous extent and internal characteristics of bone tumors. MRI is highly sensitive for the detection of bone marrow abnormalities, cortical destruction or soft tissue tumors adjacent to or infiltrating adjacent bones. (1) However, these modalities cannot assess tumor activity and 76 metabolism, which are crucial to differentiate malignancy from benignancy and to plan the first operative procedures. (2) Positron emission tomography (PET) with 2-[fluorine-2-deoxy-d-glucose (FDG) has been used extensively to differentiate malignant tumors from benign lesions in many organ systems (3) (4) (5) Its usefulness has also been reported in distinction of benign from malignant bone tumors and in the assessment of grade of musculoskeletal sarcomas. (6) (7) (8) (9) Intravenously injected FDG is first transported into cells by glucose transporters and then phosphorylated into FDG-6-phosphate by hexokinase in same way as glucose is phosphorylated into glucose-6-phosphate. While glucose-6-phosphate is further catalyzed in a normal glucose metabolism pathway, FDG-6-phosphate is not transformed by phosphoglucose isomerase and therefore remains trapped in cells. 
DIFFERENTIATION OF MALIGNANT FROM BENIGN BONE TUMORS
Since Warburg reported in 1956 that a cell line that had produced sarcoma in CH3/He mice showed higher glucose metabolism than acell line had not (12) , malignant tumors, such as hepatoma (13, 14) , leukemia (15) , colon cancer, melanoma, carcinoma of urinary bladder (14) , and so on, have been known to show high glucose metabolism.
Some authors have reported higher glucose uptake in malignant musculoskeletal tumors than in benign tumors and tried to differentiate malignant from benign tumors using an SUV cut off of 
COMPARISON OF PET-CT WITH MRIIN DISTINGUISING BENIGN VS MALIGNANT VERTIBRAL BONE DISEASE

CONCLUSION
Positron emission tomography (PET) using 18 F FDG is being used along with computed tomography (CT) and magnetic resonance imaging (MRI) in differentiation of benign and malignant intraosseous lesions. Nuclear medicine physicians should be aware of a high accumulation of FDG in some benign bone tumors and tumor like lesions, specially histocytic and Giant cell containing lesions. Dual-time point 18 F FDG PET may provide more help in this differentiation and is specially recommended for the unclear bone lesions.
